US Food and Drug Administration staff reviewers on Sunday said Pfizer-BioNTech’s Covid-19 vaccines were effective and safe for use in children aged six months to four years.
The FDA analysis of data from Pfizer’s trial was published ahead of a June 15 meeting of its outside advisers. Recommendations from the external advisers will determine the FDA’s decision on the vaccines. An early analysis of data from Pfizer-BioNTech’s vaccine based on 10 symptomatic Covid-19 cases identified when the Omicron coronavirus variant was dominant suggested a vaccine efficacy of 80.3% in the under-5 age group.Covid-19 shots for children under the age of six are yet not approved in most parts of the world.
Nous avons résumé cette actualité afin que vous puissiez la lire rapidement. Si l'actualité vous intéresse, vous pouvez lire le texte intégral ici. Lire la suite: